What the study found
Researchers randomized 186 women younger than 35 with poor ovarian-reserve parameters to 60 days of CoQ10 before IVF-ICSI or no pretreatment. The primary outcome concerned high-quality embryos. [1]
The analysis included 169 women after excluding 17 for low CoQ10 adherence. Oocyte retrieval, fertilization and embryo measures favored pretreatment, but pregnancy and live-birth comparisons did not reach statistical significance. [1]
What remains unanswered
The asymmetric exclusions can affect comparability, and the control was no pretreatment rather than a matching placebo. The authors declared no competing interests; funding was not established from the abstract. Better embryological markers cannot be described as proven live-birth improvement. [1]
A hypothetical distinction
Imagine more embryos meet a laboratory criterion but the birth comparison remains uncertain. The embryo result is relevant, yet it cannot substitute for the outcome of having a baby.
| Detail | Interpretation |
|---|---|
| 186 randomized | 169 analyzed |
| No-pretreatment control | Not matching placebo |
| Live birth | Significant benefit not established |
Sources for this article
- Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial - PubMed
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.